Not surprisingly, immunohistochemical (IHC) tumor and/or immune cell expression of PD-1 and/or PD-L1 has been associated with numerically higher response rates in checkpoint inhibitor trials [6, 9, 10]. Here, PDCD1 is linked to neoplasm.